Latest From Acrux Ltd.
Experts convened by FDA to discuss female sexual dysfunction disorders, including problems with desire and arousal, settle on endpoints contrary to new DSM, but are in line with trials of Sprout’s flibanserin, the leading drug in development.
PharmAsia News combs through earnings reports to bring you highlights on Australian biotech firms. We start with CSL Ltd, Acrux, Pharmaxis and Mesoblast for the period ended Dec. 31, 2012.
Public unlisted Australian drug development company Hunter Immunology is recommending that its shareholders accept the takeover offer from listed biotech firm Probiomics.
An Australian private member's bill which proposes a ban on the patenting of human genes and biological materials will have ramifications not just for the local R&D industries. It could change the way the country is viewed as a place for inward investment.
- Drug Delivery
- Therapeutic Areas
- Parent & Subsidiaries
- Acrux Ltd.
- Senior Management
Richard Treagus, CEO
Jon Pilcher, CFO
Nina Wilkins, PhD, Dir., Bus. Dev.
Adam Watkinson, PhD, CSO
- Contact Info
Phone: (61) 3 8379 0100
103-113 Stanley St.
West Melbourne, VIC 3003
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.